Mind Medicine (MindMed) Inc
F:MMQ

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
F:MMQ
Watchlist
Price: 6.785 EUR 1.8% Market Closed
Market Cap: 487.7m EUR
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mind Medicine (MindMed) Inc
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
F:MMQ
Accounts Payable
$2.1m
CAGR 3-Years
-28%
CAGR 5-Years
85%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accounts Payable
$9B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Accounts Payable
$3.5B
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
3%
Pfizer Inc
NYSE:PFE
Accounts Payable
$5.1B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
6%
Merck & Co Inc
NYSE:MRK
Accounts Payable
$3.6B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accounts Payable
$2.9B
CAGR 3-Years
23%
CAGR 5-Years
21%
CAGR 10-Years
11%
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
487.7m EUR
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders. The company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

MMQ Intrinsic Value
2.177 EUR
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Accounts Payable?
Accounts Payable
2.1m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Accounts Payable amounts to 2.1m USD.

What is Mind Medicine (MindMed) Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
85%

Over the last year, the Accounts Payable growth was -72%. The average annual Accounts Payable growth rates for Mind Medicine (MindMed) Inc have been -28% over the past three years , 85% over the past five years .

Back to Top